USA — Thermo Fisher Scientific and Celltrio have announced their collaboration to bring a fully automated cell culture system to biotherapeutics customers.
The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance.
Celltrio’s RoboCell systems distributed in Europe will now use Momentum software for work scheduling and data management.
Thermo Fisher will also immediately take on exclusive responsibility for sales, installation, and support of the RoboCell system in Europe, with the possibility of extending into other geographies in the future.
With the Momentum workflow scheduling software, RoboCell users may define, execute, and monitor processes and workflows with an easy-to-use interface.
The software’s intelligent data-driven decision-making capabilities and bi-directional communication also enable secure connectivity and traceability while ensuring laboratories boost their performance.
The global cell culture market size is expected to reach US$60.27 billion by 2030, expanding at a CAGR of 11.9% from 2022 to 2030, according to ResearchAndMarkets.
This can be attributed to the increase in biopharmaceutical production, advancements in vaccine research and development, and increasing focus on genetic engineering applications that rely heavily on cell culture techniques.
Similarly, with the introduction of new platforms, automation in cell line development technologies is gaining traction.
In October 2021, for example, CYTENA launched C.STATION, a fully automated cell line development platform for increasing antibody and gene therapy production. Such product launches will almost certainly increase market penetration of cell culture offerings.
Cell culture models are crucial in the development of novel therapeutics for diseases like diabetes, cancer, and Parkinson’s disease.
With a greater emphasis on research and development activities aimed at identifying therapeutic candidates for such diseases, the market for customized media for use in preclinical research is expected to grow.
Further afield, Thermo Fisher Scientific has launched its new Cell Therapy Collaboration Center Program in Singapore to accelerate cell therapy development across the Asia Pacific region.
The center, based in Singapore, will serve as the Asia Pacific hub to provide cell and gene therapy (CGT) developers with tailored support on their path to clinical manufacturing and commercial success.
From process development to technology transfer and scalability, this collaboration program will enable cell therapy innovators to accelerate the accessibility of potentially curative therapies to patients.
The program officially kicked off in October last year at the 2022 Cell & Gene Therapy Expert Forum Event with over 50 leading developers and thought leaders across the Asia Pacific region.
In Southeast Asia, non-communicable diseases (NCDs) cause an estimated nine million deaths annually along with the Asia Pacific region being home to almost half the world’s cancer cases, which is expected to increase by 35% by 2030.
The global cell & gene therapy manufacturing services market size is projected to reach US$11.5 billion by 2027 from US$5.1 billion in 2022, at a CAGR of 17.5%, according to ReportLinker.
Growth in this market can be attributed to rapidly increasing private equity and capital investment in life sciences over the last decade coupled with significant investment in cell and gene therapy companies.